BIRC5 expression is a poor prognostic marker in Ewing sarcoma

The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro

(2011) Philipp Lechler et al.   BMC CANCER

Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells

(2011) Qinwen Wang et al.   CANCER LETTERS

Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions

(2011) Do-Sim Park et al.   CLINICAL & EXPERIMENTAL METASTASIS

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

(2011) Kentaro Yamanaka et al.   CLINICAL CANCER RESEARCH

Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses

(2011) Matthaios Speletas et al.   CLINICAL IMMUNOLOGY

Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine

(2011) Matthew S. Block et al.   MELANOMA RESEARCH

Survivin Silencing as a Promising Strategy To Enhance the Sensitivity of Cancer Cells to Chemotherapeutic Agents

(2011) S. Trabulo et al.   MOLECULAR PHARMACEUTICS

Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin

(2010) Jun Zou et al.   ARCHIVES OF MEDICAL RESEARCH

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

(2010) M. Tanioka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations

(2010) K. Okamoto et al.   CANCER RESEARCH

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

(2010) Takahito Nakahara et al.   CANCER SCIENCE

Targeting insulin-like growth factor 1 receptor in sarcomas

(2010) Katia Scotlandi et al.   CURRENT OPINION IN ONCOLOGY

Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells

(2010) Zakir Khan et al.   RADIOTHERAPY AND ONCOLOGY

Survivin: A new target for anti-cancer therapy

(2009) Bríd M. Ryan et al.   CANCER TREATMENT REVIEWS

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

(2009) Karl D. Lewis et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

(2009) David O Azorsa et al.   Journal of Translational Medicine

Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy

(2008) Karl-Ludwig Schaefer et al.   EUROPEAN JOURNAL OF CANCER